Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 121-125

  Nix, David E ^a,c   Symonds, William T ^a   Hyatt, Judith M ^a   Wilton, John H ^a   Teal, Marilyn A ^b   Reidenberg, Pascale ^b   Affrime, Melton B ^b  

^a Millard Fillmore Gates Circle Hospital   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; CEFIXIME; CEFTIBUTEN; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CEFACLOR; CEFIXIME; CEFOTAXIME; CEFUROXIME; CEPHALOSPORINS; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0031031997     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kearns GL, Young RA. Ceftibuten pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1994;26(3):169-89.
2. Wiseman LR., Balfour JA. Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994;47:784-808.
3. Jones RN. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J 1995;14:577-83.
4. Barr WH, Lin CC, Radwanski E, Lim J, Symchowicz S, Affrime M. The pharmacokinetics of Ceftibuten in humans. Diagn Microbiol Infect Dis 1991;14:93-100.
5. Kelloway JS, Awni WM, Lin CC, et al. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency. Antimicrob Agents Chemother 1991;35:2267-74.
6. Fassbender M, Lode H, Schaberg T, Borner K, Koeppe P. Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 1993;16:646-53.
7. Lode H, Fassbender M, Schaberg T, Borner K, Koeppe P. Comparative pharmacokinetics of the new oral cephalosporins. Drugs 1994;47(suppl 3):10-20.
8. Colucci R, Radwanski E, Affrime MB, Lin C. The influence of food on the bioavailability of ceftibuten [abstr]. J Clin Pharmacol 1994;34:1015.
9. Konishi K, Suzuki H, Hayashi M, Saruta T. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J Antimicrob Chemother 1993;31:413-20.
10. Sommers DK, Wyk MV, Williams PEO, Harding SM. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984;25:344-7.
11. Ginsburg CM, McCracken GH, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985;28:504-7.
12. Williams PEO, Harding SM. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother 1984;13:191-6.
13. Faulkner RD, Bohaychuk W, Desjardins RE, et al. Pharmacokinetics of cefixime after once a day and twice a day dosing to steady state. J Clin Pharmacol 1987;27:807-12.
14. Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol 1988;34:525-8.
15. Faulkner RD, Bohaychuk W, Lane RA, et al. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother 1988;21:787-94.
16. Welling PG, Dean S, Selen A, Kendal MJ, Wise R. The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin. lnt J Clin Pharmacol Biopharm 1979;17(9):397-400.
17. Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Pittman KA. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1990;34:1204-9.